<p>Aquestive Therapeutics（納斯達克：AQST - 獲取免費報告）在週五向投資者發佈的一份報告中，研究分析師 Piper Sandler 將其目標價格從 5.00 美元上調至 8.00 美元，Benzinga 報道。該券商目前對該股票給予 “超配” 評級。Piper Sandler 的目標價格暗示該公司當前價格有 30.51% 的潛在上漲空間。</p>
<p>其他分析師最近也對該股票發佈了研究報告。Zacks Research 在 10 月 17 日的研究報告中將 Aquestive Therapeutics 的評級從 “持有” 上調至 “強力買入”。花旗集團在 10 月 9 日的報告中重申了對 Aquestive Therapeutics 的 “跑贏大盤” 評級。Oppenheimer 在 9 月 8 日的研究報告中將 Aquestive Therapeutics 的目標價格從 7.00 美元上調至 8.00 美元，並給予該股票 “跑贏大盤” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對 Aquestive Therapeutics 的 “賣出（d-）” 評級。最後，JMP Securities 在 10 月 9 日的研究報告中將 Aquestive Therapeutics 的目標價格從 9.00 美元上調至 12.00 美元，並給予該公司 “市場跑贏” 評級。有兩位分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Aquestive Therapeutics 的平均評級為 “買入”，共識目標價格為 10.00 美元。</p>
<p>獲取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
<p><strong>閲讀我們最新的 AQST 股票分析</strong></p>
<h2>Aquestive Therapeutics 股價上漲 2.2%</h2>
<p>AQST 的股票在週五以 6.13 美元開盤。該公司的市值為 6.1128 億美元，市盈率為-8.63，貝塔值為 1.79。Aquestive Therapeutics 的 12 個月低點為 2.12 美元，12 個月高點為 7.55 美元。該股票的 50 日移動平均線為 5.84 美元，200 日移動平均線為 4.24 美元。</p>
<p>Aquestive Therapeutics（納斯達克：AQST - 獲取免費報告）最後一次公佈財報是在 11 月 5 日，報告顯示該公司本季度每股收益（EPS）為-0.14 美元，低於分析師一致預期的-0.13 美元，差額為 0.01 美元。該公司本季度的收入為 1281 萬美元，而分析師預期為 1294 萬美元。Aquestive Therapeutics 已設定其 2025 財年的每股收益指導。股票研究分析師預測，Aquestive Therapeutics 在本年度將發佈-0.46 的每股收益。</p>
<h2>內部人士買賣情況</h2>
<p>在相關消息中，內部人士 Carl N. Kraus 在 10 月 15 日的交易中出售了 20,272 股該股票。該股票以平均價格 7.00 美元出售，總價值為 141,904.00 美元。交易後，該內部人士持有該公司 282,475 股股票，價值 1,977,325 美元。這代表其持股比例減少了 6.70%。該交易已在 SEC 的備案中披露，相關信息可通過此鏈接獲取。此外，內部人士 Peter E. Boyd 在 9 月 5 日的交易中出售了 15,000 股該公司的股票。該股票以平均價格 5.30 美元出售，總價值為 79,500.00 美元。出售後，該內部人士直接持有該公司 288,323 股股票，價值 1,528,111.90 美元。此交易代表其持股比例減少了 4.95%。該出售的披露信息可在 SEC 備案中找到。在過去一個季度中，內部人士已出售 276,770 股公司股票，價值 1,692,203 美元。8.35% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 Aquestive Therapeutics 的看法</h2>
<p>一些機構投資者和對沖基金最近買賣了 AQST 的股票。Geode Capital Management LLC 在第二季度將其在 Aquestive Therapeutics 的持股增加了 16.2%。Geode Capital Management LLC 現在擁有 1,977,001 股該公司的股票，價值 6,545,000 美元，此前在上個季度又購買了 276,295 股。Pale Fire Capital SE 在第二季度將其在 Aquestive Therapeutics 的持股增加了 25.5%。Pale Fire Capital SE 現在擁有 1,676,451 股該公司的股票，價值 5,549,000 美元，此前在此期間又購買了 340,767 股。Commonwealth Equity Services LLC 在第三季度獲得了在 Aquestive Therapeutics 的新頭寸，價值約為 5,918,000 美元。Sio Capital Management LLC 在第二季度將其在 Aquestive Therapeutics 的持股增加了 141.9%。Sio Capital Management LLC 現在擁有 947,489 股該公司的股票，價值 3,136,000 美元，此前在此期間又購買了 555,860 股。最後，Federated Hermes Inc.在第三季度獲得了在 Aquestive Therapeutics 的新股份，價值 4,381,000 美元。32.45% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Aquestive Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Aquestive Therapeutics, Inc.是一家在美國及國際上運營的製藥公司。該公司銷售 Sympazan，一種用於治療 Lennox-Gastaut 綜合症的口服可溶膜製劑；Suboxone，一種用於治療阿片類藥物依賴的舌下膜製劑；Zuplenz，一種用於治療與化療和術後恢復相關的噁心和嘔吐的口服可溶膜製劑；以及 Azstarys，一種用於治療注意力缺陷多動障礙的每日一次產品。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Aquestive Therapeutics 更好</li>
<li>如何計算股票利潤</li>
<li>為什麼投資者不應害怕微軟股票的下跌</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>DigitalOcean 的潮流已經轉變：準備迎接浪潮</li>
<li>如何購買黃金股票並投資黃金</li>
<li>CAVA 股票在財報失利後尋找方向</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Aquestive Therapeutics 嗎？</h2>
<p>在考慮 Aquestive Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Aquestive Therapeutics 並不在名單上。</p>
<p>雖然目前分析師對 Aquestive Therapeutics 的評級為買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AQST

<p>Piper Sandler 將 Aquestive Therapeutics (NASDAQ:AQST) 的目標股價從 5.00 美元上調至 8.00 美元，維持 “增持” 評級。這表明與當前價格相比，潛在上漲幅度為 30.51%。其他分析師也上調了評級，Zacks 從 “持有” 調整為 “強力買入”。該股票開盤價為 6.13 美元，市值為 6.1128 億美元。近期內部人士的銷售和機構投資表明該股票的活躍交易，平均評級為 “買入”，共識目標價為 10.00 美元</p>

<p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) had its price objective increased by research analysts at Piper Sandler from $5.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Piper Sandler's price objective would suggest a potential upside of 30.51% from the company's current price.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（納斯達克：AQST - 獲取免費報告）在週五向投資者發佈的一份報告中，研究分析師 Piper Sandler 將其目標價格從 5.00 美元上調至 8.00 美元，Benzinga 報道。該券商目前對該股票給予 “超配” 評級。Piper Sandler 的目標價格暗示該公司當前價格有 30.51% 的潛在上漲空間。</p>
</div><p>Other analysts have also recently issued research reports about the stock. Zacks Research raised shares of Aquestive Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, October 17th. Citigroup reissued an &#34;outperform&#34; rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Oppenheimer lifted their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, September 8th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities lifted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a &#34;market outperform&#34; rating in a research report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of &#34;Buy&#34; and a consensus price target of $10.00.</p>
<div class="lb-trans"><p>其他分析師最近也對該股票發佈了研究報告。Zacks Research 在 10 月 17 日的研究報告中將 Aquestive Therapeutics 的評級從 “持有” 上調至 “強力買入”。花旗集團在 10 月 9 日的報告中重申了對 Aquestive Therapeutics 的 “跑贏大盤” 評級。Oppenheimer 在 9 月 8 日的研究報告中將 Aquestive Therapeutics 的目標價格從 7.00 美元上調至 8.00 美元，並給予該股票 “跑贏大盤” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對 Aquestive Therapeutics 的 “賣出（d-）” 評級。最後，JMP Securities 在 10 月 9 日的研究報告中將 Aquestive Therapeutics 的目標價格從 9.00 美元上調至 12.00 美元，並給予該公司 “市場跑贏” 評級。有兩位分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Aquestive Therapeutics 的平均評級為 “買入”，共識目標價格為 10.00 美元。</p>
</div><p>Get <strong>Aquestive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Stock Analysis on AQST</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 AQST 股票分析</strong></p>
</div><h2>Aquestive Therapeutics Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Aquestive Therapeutics 股價上漲 2.2%</h2>
</div><p>Shares of AQST opened at $6.13 on Friday. The firm has a market cap of $611.28 million, a P/E ratio of -8.63 and a beta of 1.79. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The stock's 50 day moving average is $5.84 and its two-hundred day moving average is $4.24.</p>
<div class="lb-trans"><p>AQST 的股票在週五以 6.13 美元開盤。該公司的市值為 6.1128 億美元，市盈率為-8.63，貝塔值為 1.79。Aquestive Therapeutics 的 12 個月低點為 2.12 美元，12 個月高點為 7.55 美元。該股票的 50 日移動平均線為 5.84 美元，200 日移動平均線為 4.24 美元。</p>
</div><p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analysts' expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（納斯達克：AQST - 獲取免費報告）最後一次公佈財報是在 11 月 5 日，報告顯示該公司本季度每股收益（EPS）為-0.14 美元，低於分析師一致預期的-0.13 美元，差額為 0.01 美元。該公司本季度的收入為 1281 萬美元，而分析師預期為 1294 萬美元。Aquestive Therapeutics 已設定其 2025 財年的每股收益指導。股票研究分析師預測，Aquestive Therapeutics 在本年度將發佈-0.46 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In related news, insider Carl N. Kraus sold 20,272 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total value of $141,904.00. Following the transaction, the insider owned 282,475 shares of the company's stock, valued at $1,977,325. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Peter E. Boyd sold 15,000 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the sale, the insider directly owned 288,323 shares in the company, valued at $1,528,111.90. This trade represents a 4.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 276,770 shares of company stock worth $1,692,203. 8.35% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Carl N. Kraus 在 10 月 15 日的交易中出售了 20,272 股該股票。該股票以平均價格 7.00 美元出售，總價值為 141,904.00 美元。交易後，該內部人士持有該公司 282,475 股股票，價值 1,977,325 美元。這代表其持股比例減少了 6.70%。該交易已在 SEC 的備案中披露，相關信息可通過此鏈接獲取。此外，內部人士 Peter E. Boyd 在 9 月 5 日的交易中出售了 15,000 股該公司的股票。該股票以平均價格 5.30 美元出售，總價值為 79,500.00 美元。出售後，該內部人士直接持有該公司 288,323 股股票，價值 1,528,111.90 美元。此交易代表其持股比例減少了 4.95%。該出售的披露信息可在 SEC 備案中找到。在過去一個季度中，內部人士已出售 276,770 股公司股票，價值 1,692,203 美元。8.35% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Aquestive Therapeutics 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of AQST. Geode Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after buying an additional 276,295 shares during the last quarter. Pale Fire Capital SE lifted its stake in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company's stock valued at $5,549,000 after purchasing an additional 340,767 shares during the period. Commonwealth Equity Services LLC acquired a new position in Aquestive Therapeutics during the third quarter valued at approximately $5,918,000. Sio Capital Management LLC grew its stake in Aquestive Therapeutics by 141.9% during the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock worth $3,136,000 after buying an additional 555,860 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at $4,381,000. 32.45% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買賣了 AQST 的股票。Geode Capital Management LLC 在第二季度將其在 Aquestive Therapeutics 的持股增加了 16.2%。Geode Capital Management LLC 現在擁有 1,977,001 股該公司的股票，價值 6,545,000 美元，此前在上個季度又購買了 276,295 股。Pale Fire Capital SE 在第二季度將其在 Aquestive Therapeutics 的持股增加了 25.5%。Pale Fire Capital SE 現在擁有 1,676,451 股該公司的股票，價值 5,549,000 美元，此前在此期間又購買了 340,767 股。Commonwealth Equity Services LLC 在第三季度獲得了在 Aquestive Therapeutics 的新頭寸，價值約為 5,918,000 美元。Sio Capital Management LLC 在第二季度將其在 Aquestive Therapeutics 的持股增加了 141.9%。Sio Capital Management LLC 現在擁有 947,489 股該公司的股票，價值 3,136,000 美元，此前在此期間又購買了 555,860 股。最後，Federated Hermes Inc.在第三季度獲得了在 Aquestive Therapeutics 的新股份，價值 4,381,000 美元。32.45% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>關於 Aquestive Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.是一家在美國及國際上運營的製藥公司。該公司銷售 Sympazan，一種用於治療 Lennox-Gastaut 綜合症的口服可溶膜製劑；Suboxone，一種用於治療阿片類藥物依賴的舌下膜製劑；Zuplenz，一種用於治療與化療和術後恢復相關的噁心和嘔吐的口服可溶膜製劑；以及 Azstarys，一種用於治療注意力缺陷多動障礙的每日一次產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Aquestive Therapeutics</li>
<li>How to Calculate Stock Profit</li>
<li>Why Investors Shouldn’t Fear the Dip in Microsoft Stock</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>CAVA Stock Looking for Direction After Earnings Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Aquestive Therapeutics 更好</li>
<li>如何計算股票利潤</li>
<li>為什麼投資者不應害怕微軟股票的下跌</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>DigitalOcean 的潮流已經轉變：準備迎接浪潮</li>
<li>如何購買黃金股票並投資黃金</li>
<li>CAVA 股票在財報失利後尋找方向</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AQST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aquestive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aquestive Therapeutics 嗎？</h2>
</div><p>Before you consider Aquestive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aquestive Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Aquestive Therapeutics 並不在名單上。</p>
</div><p>While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然目前分析師對 Aquestive Therapeutics 的評級為買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aquestive Therapeutics（NASDAQ:AQST）被派傑公司給予新的 8.00 美元目標價